Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADVM Adverum Biotechnologies	$2.29 +0.4%	$2.57	$1.78 ▼ $10.14	$47.73M	0.7	267,722 shs	90,936 shs
ALGS Aligos Therapeutics	$7.28 -1.5%	$6.28	$3.76 ▼ $46.80	$44.49M	2.77	210,088 shs	46,730 shs
CLLS Cellectis	$1.61 +3.5%	$1.48	$1.10 ▼ $2.43	$89.21M	2.91	142,436 shs	66,266 shs
INBX Inhibrx Biosciences	$15.65 +6.6%	$13.21	$10.80 ▼ $17.79	$226.25M	-0.04	96,113 shs	33,457 shs
KRYS Krystal Biotech	$140.56 +1.1%	$139.58	$122.80 ▼ $219.34	$4.06B	0.67	286,672 shs	90,546 shs

2025 Gold Forecast: A Perfect Storm for Demand

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADVM Adverum Biotechnologies	+6.05%	-10.24%	+3.17%	-46.48%	-67.29%
ALGS Aligos Therapeutics	+2.50%	-10.32%	+37.11%	-2.51%	-19.89%
CLLS Cellectis	+1.64%	+5.44%	+7.12%	+23.02%	-19.90%
INBX Inhibrx Biosciences	+2.80%	-0.61%	+8.19%	+4.04%	+6.77%
KRYS Krystal Biotech	+1.13%	-3.24%	+9.41%	-23.20%	-23.73%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADVM Adverum Biotechnologies	4.3193 of 5 stars	3.4	3.0	4.8	1.7	2.5	0.6
ALGS Aligos Therapeutics	4.2001 of 5 stars	3.5	3.0	4.8	2.7	1.7	0.0
CLLS Cellectis	3.0072 of 5 stars	3.5	3.0	0.0	2.5	2.5	0.6
INBX Inhibrx Biosciences	1.5372 of 5 stars	0.0	1.0	4.6	2.0	1.7	1.3
KRYS Krystal Biotech	4.6181 of 5 stars	3.5	1.0	4.7	3.1	2.5	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADVM Adverum Biotechnologies	2.80	Moderate Buy	$23.80	939.30% Upside
ALGS Aligos Therapeutics	3.00	Buy	$70.00	861.54% Upside
CLLS Cellectis	3.00	Buy	$4.00	149.22% Upside
INBX Inhibrx Biosciences	2.00	Hold	N/A	N/A
KRYS Krystal Biotech	3.00	Buy	$211.13	50.21% Upside

Current Analyst Ratings Breakdown

Latest CLLS, INBX, KRYS, ADVM, and ALGS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/26/2025	ADVM Adverum Biotechnologies	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$16.00 ➝ $12.00
6/24/2025	KRYS Krystal Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$240.00
5/16/2025	KRYS Krystal Biotech	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$215.00 ➝ $155.00
5/15/2025	ADVM Adverum Biotechnologies	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Perform ➝ Sector Perform	$5.00 ➝ $4.00
5/15/2025	ADVM Adverum Biotechnologies	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$33.00 ➝ $33.00
5/15/2025	ADVM Adverum Biotechnologies	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00
5/15/2025	INBX Inhibrx Biosciences	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform
5/13/2025	CLLS Cellectis	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$5.00 ➝ $4.00
5/7/2025	KRYS Krystal Biotech	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$195.00 ➝ $189.00
5/7/2025	KRYS Krystal Biotech	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$219.00 ➝ $219.00
5/6/2025	KRYS Krystal Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$240.00 ➝ $240.00

(Data available from 7/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADVM Adverum Biotechnologies	$1M	47.84	N/A	N/A	$3.40 per share	0.67
ALGS Aligos Therapeutics	$3.94M	11.29	N/A	N/A	($7.50) per share	-0.97
CLLS Cellectis	$49.22M	1.81	N/A	N/A	$2.36 per share	0.68
INBX Inhibrx Biosciences	$200K	1,132.70	$130.38 per share	0.12	$9.23 per share	1.70
KRYS Krystal Biotech	$290.52M	13.98	$4.74 per share	29.64	$32.90 per share	4.27

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADVM Adverum Biotechnologies	-$130.93M	-$6.40	N/A	N/A	N/A	N/A	-130.53%	-66.31%	8/11/2025 (Estimated)
ALGS Aligos Therapeutics	-$131.21M	-$17.51	N/A	N/A	N/A	-1,628.75%	14.67%	7.19%	8/5/2025 (Estimated)
CLLS Cellectis	-$36.76M	-$0.86	N/A	N/A	N/A	-114.82%	-62.55%	-21.19%	8/5/2025 (Estimated)
INBX Inhibrx Biosciences	$1.69B	$116.75	0.13	N/A	N/A	N/A	-85.12%	-58.90%	8/12/2025 (Estimated)
KRYS Krystal Biotech	$89.16M	$4.16	33.78	13.94	N/A	37.17%	14.64%	13.28%	8/4/2025 (Estimated)

Latest CLLS, INBX, KRYS, ADVM, and ALGS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q4 2024	INBX Inhibrx Biosciences	-$2.55	-$2.80	-$0.25	-$2.80	N/A	N/A
5/12/2025	Q1 2025	CLLS Cellectis	-$0.1540	-$0.18	-$0.0260	-$0.18	$12.71 million	$12.03 million
5/6/2025	Q1 2025	ALGS Aligos Therapeutics	-$2.80	-$2.11	+$0.69	-$2.11	$0.33 million	$0.31 million
5/6/2025	Q1 2025	KRYS Krystal Biotech	$1.38	$1.20	-$0.18	$1.20	$98.66 million	$88.18 million
4/15/2025	Q4 2024	ADVM Adverum Biotechnologies	-$1.34	-$1.96	-$0.62	-$1.96	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADVM Adverum Biotechnologies	N/A	N/A	N/A	N/A	N/A
ALGS Aligos Therapeutics	N/A	N/A	N/A	N/A	N/A
CLLS Cellectis	N/A	N/A	N/A	N/A	N/A
INBX Inhibrx Biosciences	N/A	N/A	N/A	N/A	N/A
KRYS Krystal Biotech	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADVM Adverum Biotechnologies	N/A	3.57	3.57
ALGS Aligos Therapeutics	N/A	7.56	7.56
CLLS Cellectis	0.44	1.67	1.67
INBX Inhibrx Biosciences	1.04	5.12	5.12
KRYS Krystal Biotech	N/A	9.65	9.27

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADVM Adverum Biotechnologies	48.17%
ALGS Aligos Therapeutics	60.43%
CLLS Cellectis	63.90%
INBX Inhibrx Biosciences	82.46%
KRYS Krystal Biotech	86.29%

Insider Ownership

Company	Insider Ownership
ADVM Adverum Biotechnologies	6.00%
ALGS Aligos Therapeutics	4.80%
CLLS Cellectis	16.41%
INBX Inhibrx Biosciences	N/A
KRYS Krystal Biotech	13.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADVM Adverum Biotechnologies	190	20.89 million	19.64 million	Optionable
ALGS Aligos Therapeutics	90	6.11 million	5.82 million	No Data
CLLS Cellectis	290	55.58 million	46.46 million	Optionable
INBX Inhibrx Biosciences	166	14.48 million	N/A	Optionable
KRYS Krystal Biotech	210	28.90 million	24.94 million	Optionable

CLLS, INBX, KRYS, ADVM, and ALGS Headlines

Recent News About These Companies

Krystal Biotech Q2 EPS Estimate Lowered by HC Wainwright

July 2 at 7:41 AM | marketbeat.com

Dino A Rossi Exhibits Confidence With An Acquisition Of Krystal Biotech Stock Options Worth $6K

July 1 at 12:02 PM | benzinga.com

Insider Decision Unfolding At Krystal Biotech: Christopher Mason Exercises Options, Resulting In $0

July 1 at 12:02 PM | benzinga.com

HC Wainwright Reduces Earnings Estimates for Krystal Biotech

July 1 at 8:00 AM | marketbeat.com

Lisanti Capital Growth LLC Acquires Shares of 30,410 Krystal Biotech, Inc. (NASDAQ:KRYS)

June 29 at 6:33 AM | marketbeat.com

Krystal Biotech, Inc. (NASDAQ:KRYS) Receives $211.13 Consensus Target Price from Brokerages

June 28, 2025 | americanbankingnews.com

Strength Seen in Krystal Biotech (KRYS): Can Its 4.2% Jump Turn into More Strength? - Nasdaq

June 27, 2025 | nasdaq.com

3 Promising Genomics Stocks to Keep an Eye On in 2025

June 27, 2025 | zacks.com

Krystal Biotech doses first patient in phase 3 trial IOLITE

June 27, 2025 | ophthalmologytimes.comO

Krystal Biotech, Inc.: Krystal Biotech Announces First Patient Dosed in Phase 3 Clinical Trial of KB803 for the Treatment and Prevention of Corneal Abrasions in Patients with ...

June 26, 2025 | finanznachrichten.de

KRYS Up 4% on Initiating Dosing in Rare Eye Disease Phase III Study

June 25, 2025 | zacks.com

Strength Seen in Krystal Biotech (KRYS): Can Its 4.2% Jump Turn into More Strength?

June 25, 2025 | zacks.com

Wealthquest Corp Makes New $347,000 Investment in Krystal Biotech, Inc. (NASDAQ:KRYS)

June 25, 2025 | marketbeat.com

Krystal Biotech, Inc. (NASDAQ:KRYS) Receives Average Rating of "Buy" from Analysts

June 25, 2025 | marketbeat.com

Krystal Biotech Inc News (KRYS) - Investing.com

June 24, 2025 | investing.com

Cell-based, gene therapy skin grafts heal large epidermolysis bullosa wounds

June 24, 2025 | healio.comH

Krystal Biotech's (KRYS) "Buy" Rating Reiterated at HC Wainwright

June 24, 2025 | marketbeat.com

Krystal Biotech, Inc. Doses First Patient in Phase 3 Trial Evaluating KB803 for Corneal Abrasion Treatment in Dystrophic Epidermolysis Bullosa Patients

June 24, 2025 | quiverquant.comQ

Krystal Biotech Announces First Patient Dosed in Phase 3 Clinical Trial of KB803 for the Treatment and Prevention of Corneal Abrasions in Patients with Dystrophic Epidermolysis Bullosa

June 24, 2025 | globenewswire.com

Janney Montgomery Scott LLC Has $8.28 Million Stake in Krystal Biotech, Inc. (NASDAQ:KRYS)

June 21, 2025 | marketbeat.com

2KRYS : $100 Invested In This Stock 5 Years Ago Would Be Worth This Much Today

June 20, 2025 | benzinga.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLLS, INBX, KRYS, ADVM, and ALGS Company Descriptions

Adverum Biotechnologies NASDAQ:ADVM

$2.29 +0.01 (+0.44%)

As of 02:55 PM Eastern

Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.

Aligos Therapeutics NASDAQ:ALGS

$7.28 -0.11 (-1.49%)

As of 02:50 PM Eastern

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Cellectis NASDAQ:CLLS

$1.60 +0.06 (+3.55%)

As of 02:52 PM Eastern

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Inhibrx Biosciences NASDAQ:INBX

$15.64 +0.98 (+6.65%)

As of 02:55 PM Eastern

Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.

Krystal Biotech NASDAQ:KRYS

$140.56 +1.55 (+1.11%)

As of 02:55 PM Eastern

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time